Mochida Pharmaceutical Co., Ltd. has resolved to repurchase up to 530,000 shares with a total upper limit of 2,000,000,000 yen from May 18, 2026, to December 18, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4534-20260330-03.pdf","jir_short_summary":"Mochida Pharmaceutical Co., Ltd. has resolved to repurchase up to 530,000 shares with a total upper limit of 2,000,000,000 yen from May 18, 2026, to December 18, 2026.","jir_summary":"### Overview of Capital Policy\nMochida Pharmaceutical Co., Ltd. resolved at the Board of Directors meeting on March 30, 2026, to repurchase treasury stock aimed at expanding the shareholder base and improving stock liquidity. The target shares are our common stock, with an upper limit of 530,000 shares (1.50% of the total number of issued shares) and a total acquisition price upper limit of 2,000,000,000 yen. The acquisition period is from May 18, 2026, to December 18, 2026, and will be conducted through market purchases on the Tokyo Stock Exchange.\n\n### Impact on Shareholders and Future Outlook\nThis share buyback aims to mitigate supply-demand impacts caused by stock selling, enhance shareholder returns, and improve capital efficiency. As of February 28, 2026, the number of treasury shares held was 940,273 shares, and this acquisition may increase the number of treasury shares. Depending on market conditions, some or all acquisitions may not be executed; however, it will be carried out as part of agile capital policy.","jir_financial_highlights":"Type of Shares to be Acquired: Our common stock (Unknown)\nTotal Number of Shares to be Acquired: 530,000 shares (upper limit) (Unknown)\nTotal Acquisition Price: 2,000,000,000 yen (upper limit) (Unknown)\nAcquisition Period: From May 18, 2026, to December 18, 2026 (Unknown)\nTotal Number of Issued Shares (excluding treasury stock): 35,449,727 shares (Unknown)\nNumber of Treasury Stock: 940,273 shares (Unknown)","jir_category":"","jir_hashtags":"#MochidaPharmaceuticalCoLtd, #ShareBuyback, #CapitalPolicy, #JapaneseStocks","jir_key_figures":"Maximum number of shares to be acquired: 530,000 shares (1.50% of the total issued shares)\nMaximum acquisition price: 2,000,000,000 yen\nAcquisition period: From May 18, 2026, to December 18, 2026","jir_meta_title":"Mochida Pharmaceutical Co., Ltd. Resolves Share Buyback with Upper Limits of 530,000 Shares and 2 Billion Yen (2026)","jir_meta_description":"Mochida Pharmaceutical Co., Ltd. has resolved to repurchase up to 530,000 shares and 2 billion yen in total from May 18 to December 18, 2026, as part of its capital policy aimed at enhancing shareholder returns and capital efficiency.","jir_og_title":"Mochida Pharmaceutical Announces Share Buyback (530,000 Shares, 2 Billion Yen Upper Limit)","jir_og_description":"Mochida Pharmaceutical Co., Ltd. plans to conduct a share buyback from May to December 2026 to improve shareholder returns and capital efficiency.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-37783","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n